[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biliary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biliary-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100450163","optimizing-the-evaluation-and-management-of-patients-with-suspected-choledocholithiasis-100450163",false,"NCT05141916","Optimizing the Evaluation and Management of Patients With Suspected Choledocholithiasis","Inclusion Criteria:\n\n* Patients with suspected choledocholithiasis, regardless of probability\n* age 18 years old or older\n* able to give informed consent to involvement (in the prospective validation phase).\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent;\n* age \\\u003C 18 years;\n* suspected or proven cholangitis;\n* previous ERCP with sphincterotomy;\n* prior diagnosis or management of choledocholithiasis;\n* outpatient status;\n* out-of-province status (prohibiting full medical record access).","ALL","18 Years",{"count":18,"type":19},2000,"ESTIMATED","6 Months","OBSERVATIONAL","Choledocholithiasis (stone(s) in the common bile duct) is common. Untreated or missed, choledocholithiasis has high morbidity and mortality. Endoscopic retrograde cholangio-pancreatography (ERCP) is recognized as the first-line modality for management. While effective, ERCP is associated with adverse events. Thus, the selection of patients for ERCP should be accompanied by a high pre-test suspicion of choledocholithiasis.\n\nCholedocholithiasis is suspected based on clinical, biochemical and radiographic findings. The most relied-upon strategy for risk stratification of choledocholithiasis is based on guidelines from The American Society for Gastrointestinal Endoscopy (ASGE). In it, clinical predictors are defined as \"very strong\", \"strong\" or \"moderate\", and the presence of one or more of these is meant to suggest \"high\" or \"intermediate\" probability of choledocholithiasis.\n\nA knowledge gap exists in the performance characteristics of intermediate-probability criteria, where overall accuracy is \\\u003C50% from limited data. Patients in this group are recommended to a) undergo endoscopic ultrasound (EUS) or magnetic resonance cholangio-pancreatography (MRCP), b) undergo cholecystectomy with intra-operative cholangiography (IOC), or c) proceed directly to ERCP. At centres where EUS and MRCP are readily available, these are preferred options, as they are least invasive and sensitive; however, they are often unavailable. Thus, in clinical practice, a high proportion of intermediate-risk patients ultimately proceed directly to ERCP, where likelihood of benefit is only moderate, while procedural risk remains.\n\nThe role of liver enzyme changes has not been evaluated; however, dynamic changes may offer another method for evaluating patients at intermediate risk of CBD stones that is safe and available. Incorporation of dynamic liver enzymes may improve the test-performance characteristics of the existing framework.",[24,25],"Biliary Disease","Choledocholithiasis","RECRUITING","2026-04-28",{"date":29,"type":30},"2026-04-29","ACTUAL",{"date":32,"type":30},"2019-02-25",{"date":34,"type":19},"2029-06-30",{"name":36,"class":37},"University of Calgary","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":38},"100382434","calgary-registry-for-advanced-and-therapeutic-endoscopy-100382434","NCT04259580","Calgary Registry for Advanced and Therapeutic Endoscopy","CReATE","Inclusion Criteria:\n\n* any standard indication for ERCP, in the absence of standard contraindications;\n* age 18 years or over;\n* ability and willingness to give informed consent to be included in the registry and\u002For to involvement in one (or more) prospective sub-studies, or accompaniment by a surrogate who is willing and able to provide consent.\n\nExclusion Criteria:\n\n-none other than inverses of above.",{"count":47,"type":19},6000,"30 Days","The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.",[24,51],"Pancreatic Diseases",{"date":29,"type":30},{"date":54,"type":30},"2018-09-01",{"date":56,"type":19},"2030-12-31",{"name":36,"class":37},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":38},"100582259","phase-3-evaluating-the-safety-and-efficacy-of-duloxetine-in-the-prevention-of-post-endoscopic-retrograde-cholangiopancreatography-pancreatitis-100582259","NCT06860984","Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Age more than 18 years old.\n* Gender: Males and Females\n* Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.\n* Blood amylase and lipase levels before ERCP are within the normal limits\n\nExclusion Criteria:\n\n* Uncontrolled diabetes mellitus (DM)\n* Severe bleeding tendency\n* Impaired renal function (serum creatinine \\> 2 mg\u002FdL), (creatinine clearance \\\u003C30 ml\u002Fmin)\n* Patients with severe heart disease.\n* Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.\n* Currently pregnant or nursing\n* Admission due to established pancreatitis before ECRP\n* Unwillingness to undergo ERCP.","65 Years",{"count":66,"type":19},44,"INTERVENTIONAL",[69],"PHASE3","Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.",[24],"2025-11-17",{"date":74,"type":30},"2025-11-18",{"date":76,"type":30},"2025-03-10",{"date":78,"type":19},"2026-07-10",{"name":80,"class":37},"Tanta University"]